Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
8
2
2020
medline:
10
2
2021
entrez:
8
2
2020
Statut:
ppublish
Résumé
Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.
Identifiants
pubmed: 32032174
doi: 10.1097/INF.0000000000002568
pmc: PMC7182240
pii: 00006454-202004000-00009
doi:
Substances chimiques
Antifungal Agents
0
Anidulafungin
9HLM53094I
Banques de données
ClinicalTrials.gov
['NCT00761267']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-309Références
Pediatrics. 2009 Mar;123(3):877-84
pubmed: 19255017
J Pediatr Pharmacol Ther. 2012 Apr;17(2):189-95
pubmed: 23118673
Clin Infect Dis. 2003 Sep 1;37(5):634-43
pubmed: 12942393
J Pediatr. 2013 Oct;163(4):961-7.e3
pubmed: 23726546
Clin Pharmacol Ther. 2011 May;89(5):702-7
pubmed: 21412233
N Engl J Med. 2007 Jun 14;356(24):2472-82
pubmed: 17568028
Gut. 1993 Apr;34(4):565-6
pubmed: 8491409
Clin Infect Dis. 2005 Nov 1;41(9):1232-9
pubmed: 16206095
Pediatr Infect Dis J. 2019 Mar;38(3):275-279
pubmed: 30418357